Testing alpibectir plus ethionamide for new TB
Treatments studied
Part of Infections, Lungs & breathing clinical trials.
This study tests an experimental oral TB drug called alpibectir given together with ethionamide for people with newly diagnosed lung TB. The goal is to see how well the combination works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with lung TB and have not yet started treatment.
- Your TB bacteria are sensitive to the drugs rifampicin and isoniazid.
- You can produce enough sputum (phlegm) for testing.
- You are willing to use effective birth control during the study (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests different treatment plans for people with tuberculosis (TB) that can be cured with standard medicines. It aims to find the best treatment for each person based on their risk score, which may lead to shorter or more effective treatment.
This study tests whether adding the cholesterol drug atorvastatin to standard TB treatment helps people recover faster. It is for people with newly diagnosed, drug-sensitive tuberculosis who have not yet started treatment.
This trial tests a new “triple-dose” set of medicines to treat people whose tuberculosis (TB) has come back in the lungs. If you qualify, the goal is to improve cure rates and reduce the chance of TB returning again.
This trial tests a shorter treatment for children with tuberculosis (TB) that is not drug-resistant. It aims to find out if a shorter regimen works as well as the standard longer one, making treatment easier for children and their families.
This study tests new combinations of drugs for treating pulmonary tuberculosis (TB). The goal is to find more effective and safer treatments than the current standard.
This trial tests a new drug, RESP30TB, to see if it is safe, tolerable, and can quickly kill TB bacteria in people with newly diagnosed, rifampicin-susceptible pulmonary TB. You may be eligible if you can produce sputum and meet other health criteria.
Hear when a new Tuberculosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.